 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for GGN |
 Gene summary |
| Basic gene information | Gene symbol | GGN |
| Gene name | gametogenetin | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 19q13.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_152657.3, NM_182477.1, | |
| Description | - | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 609966 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000179168 | ||
| HPRD : 17036 | ||
| Vega : OTTHUMG00000182080 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GGN | |
| BioGPS: 199720 | ||
| Pathway | NCI Pathway Interaction Database: GGN | |
| KEGG: GGN | ||
| REACTOME: GGN | ||
| Pathway Commons: GGN | ||
| Context | iHOP: GGN | |
| ligand binding site mutation search in PubMed: GGN | ||
| UCL Cancer Institute: GGN | ||
| Assigned class in TissGDB* | B | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of GGN | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for GGN |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| COAD | -1.576602104 | -2.771432873 | 1.194830769 | 3.75E-07 | 2.31E-06 |
| Top |
| TissGene-miRNA for GGN |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for GGN |
| TissGeneSNV for GGN |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.A480P | ACC | 3 |
| p.A513V | STAD | 2 |
| p.S267L | LUAD | 1 |
| p.P439Q | COAD | 1 |
| p.N610T | KIRC | 1 |
| p.I631M | CESC | 1 |
| p.P96L | SKCM | 1 |
| p.R334W | STAD | 1 |
| p.P293H | LUAD | 1 |
| p.L73P | LIHC | 1 |
| p.G275D | HNSC | 1 |
| p.R187K | BLCA | 1 |
| p.P175L | SKCM | 1 |
| p.P429Q | ESCA | 1 |
| p.Q492P | COAD | 1 |
| p.A115V | STAD | 1 |
| p.A196T | LIHC | 1 |
| p.E425K | STAD | 1 |
| p.A382T | ACC | 1 |
| p.A224V | THCA | 1 |
| p.S508L | STAD | 1 |
| p.R207H | STAD | 1 |
| p.G214S | LUAD | 1 |
| p.P557S | STAD | 1 |
| p.L239M | HNSC | 1 |
| p.G218R | THYM | 1 |
| p.T538I | COAD | 1 |
| p.P429Q | LUAD | 1 |
| p.G368E | HNSC | 1 |
| p.A264V | HNSC | 1 |
| p.A552S | UCEC | 1 |
| p.A196T | SARC | 1 |
| p.P118S | LUAD | 1 |
| p.S6L | BLCA | 1 |
| p.G314E | SKCM | 1 |
| p.L543V | LUAD | 1 |
| p.C594X | SKCM | 1 |
| p.Q18K | COAD | 1 |
| p.W353G | UVM | 1 |
| p.Q492P | PAAD | 1 |
| p.T577I | UCEC | 1 |
| p.A160T | SKCM | 1 |
| p.A552D | SARC | 1 |
| p.T555A | STAD | 1 |
| p.D491N | CESC | 1 |
| p.S327L | ESCA | 1 |
| p.P376L | STAD | 1 |
| p.A356T | UCEC | 1 |
| p.P438L | LUAD | 1 |
| p.E320K | DLBC | 1 |
| p.A569D | LIHC | 1 |
| p.G563R | SKCM | 1 |
| p.N367S | SKCM | 1 |
| p.P507S | ACC | 1 |
| p.V611I | KIRC | 1 |
| p.R300C | STAD | 1 |
| p.R581C | SARC | 1 |
| p.R207H | COAD | 1 |
| p.R606S | LUSC | 1 |
| p.G218R | UCEC | 1 |
| p.G368R | LUAD | 1 |
| p.M61T | ESCA | 1 |
| p.A333D | KIRP | 1 |
| p.G314R | KIRC | 1 |
| p.G368R | HNSC | 1 |
| p.P158R | LUAD | 1 |
| p.G272R | HNSC | 1 |
| p.F586L | HNSC | 1 |
| p.C594* | SKCM | 1 |
| Top |
| TissGeneCNV for GGN |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for GGN |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for GGN |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| GGN, FANCL, GGNBP2, OAZ3 (tumor) | GGN, FANCL, GGNBP2, OAZ3 (normal) |
 |  |
| Top |
| TissGeneProg for GGN |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for GGN |
| TissGeneDrug for GGN |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for GGN |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0376358 | Malignant neoplasm of prostate | 10 | BeFree |
| umls:C0600139 | Prostate carcinoma | 10 | BeFree |
| umls:C0021364 | Male infertility | 5 | BeFree |
| umls:C0010417 | Cryptorchidism | 3 | BeFree |
| umls:C1691215 | Penile hypospadias | 3 | BeFree |
| umls:C0452147 | Hypospadias, penoscrotal | 2 | BeFree |
| umls:C0848558 | Hypospadias | 2 | BeFree |
| umls:C1704272 | Benign Prostatic Hyperplasia | 2 | BeFree |
| umls:C0000768 | Congenital Abnormality | 1 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 1 | BeFree |
| umls:C0007103 | Malignant neoplasm of endometrium | 1 | BeFree |
| umls:C0007138 | Carcinoma, Transitional Cell | 1 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 1 | BeFree |
| umls:C0028754 | Obesity | 1 | BeFree |
| umls:C0039585 | Androgen-Insensitivity Syndrome | 1 | BeFree |
| umls:C0042755 | Virilism | 1 | BeFree |
| umls:C0242339 | Dyslipidemias | 1 | BeFree |
| umls:C0311277 | Obesity, Abdominal | 1 | BeFree |
| umls:C0476089 | Endometrial Carcinoma | 1 | BeFree |
| umls:C0678222 | Breast Carcinoma | 1 | BeFree |
| umls:C0852654 | 21-hydroxylase deficiency | 1 | BeFree |
| umls:C0855197 | Testicular malignant germ cell tumor | 1 | BeFree |
| umls:C0936016 | Testicular Feminization | 1 | BeFree |
| umls:C1883486 | Uterine Corpus Cancer | 1 | BeFree |
| umls:C2145472 | Urothelial Carcinoma | 1 | BeFree |
| umls:C2936858 | Congenital adrenal hyperplasia due to 21 hydroxylase deficiency | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |